Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

  • Ralf Gold1Email author,
  • Ernst-Wilhelm Radue2,
  • Gavin Giovannoni3,
  • Krzysztof Selmaj4,
  • Eva Havrdova5,
  • Dusan Stefoski6,
  • Till Sprenger2, 7,
  • Xavier Montalban8,
  • Stanley Cohan9,
  • Kimberly Umans10,
  • Steven J. Greenberg11,
  • Gulden Ozen10 and
  • Jacob Elkins10
BMC NeurologyBMC series – open, inclusive and trusted201616:117

https://doi.org/10.1186/s12883-016-0635-y

Received: 25 October 2015

Accepted: 12 July 2016

Published: 26 July 2016

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
25 Oct 2015 Submitted Original manuscript
4 Feb 2016 Reviewed Reviewer Report - Lekha Pandit
10 Feb 2016 Reviewed Reviewer Report - Vijayshree Yadav
3 Mar 2016 Reviewed Reviewer Report - Daniel M Harrison
15 Apr 2016 Author responded Author comments - Ralf Gold
Resubmission - Version 2
15 Apr 2016 Submitted Manuscript version 2
22 Jun 2016 Author responded Author comments - Ralf Gold
Resubmission - Version 3
22 Jun 2016 Submitted Manuscript version 3
Publishing
12 Jul 2016 Editorially accepted
26 Jul 2016 Article published 10.1186/s12883-016-0635-y

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany
(2)
Medical Image Analysis Center, University Hospital Basel, Basel, Switzerland
(3)
Queen Mary University of London, Blizard Institute, London School of Medicine and Dentistry, London, UK
(4)
Medical University of Lodz, Lodz, Poland
(5)
First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
(6)
Rush University Medical Center, Chicago, USA
(7)
DKD Helios Klinik Wiesbaden, Wiesbaden, Germany
(8)
Hospital Vall d’Hebron University, Barcelona, Spain
(9)
Providence Multiple Sclerosis Center, Portland, USA
(10)
Biogen, Cambridge, USA
(11)
AbbVie Biotherapeutics Inc., Redwood, USA

Advertisement